Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830973 · ClinicalTrials.gov registry record
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
A clinical trial, sponsored by Medco Health Solutions.
- Completed
- Registry status
- 184
- Enrollment target
NCT00830973: Completed study, sponsored by Medco Health Solutions.
NCT00830973 is a clinical trial that has completed, run by Medco Health Solutions. The registered enrollment target is 184 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00830973 has completed, sponsored by Medco Health Solutions.
- COMPLETED
- Registry status
- 184 participants
- Enrollment target
Study Summary
This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.
Interventions
- OTHER Poor Metabolism Status Follow Up Therapy Considerations
- OTHER CYP2D6 Inhibiting Drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-01 |
What the finished NCT00830973 record still lists
NCT00830973 is an observational study that tracks outcomes without assigning an intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Poor Metabolism Status Follow Up Therapy Considerations is the first listed.
NCT00830973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00830973 about?
NCT00830973 is a clinical study titled "The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer". This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.
What is the current status of trial NCT00830973?
This trial is currently completed. The enrollment target is 184 participants. The study started on 2007-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00830973?
The interventions under investigation include: Poor Metabolism Status Follow Up Therapy Considerations (OTHER), CYP2D6 Inhibiting Drugs (OTHER).
Who is sponsoring clinical trial NCT00830973?
This trial is sponsored by Medco Health Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia